**Core Concept**
Psoriatic arthropathy, a form of spondyloarthritis, is a chronic inflammatory condition characterized by joint inflammation and skin manifestations in patients with psoriasis. The treatment of psoriatic arthropathy involves managing both the skin and joint symptoms effectively.

**Why the Correct Answer is Right**
The first-line treatment for psoriatic arthropathy often involves the use of disease-modifying antirheumatic drugs (DMARDs) or biologic agents that target tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17), or other pro-inflammatory cytokines. Among the biologic agents, etanercept, adalimumab, and infliximab have been shown to be effective in reducing joint inflammation and improving skin symptoms in patients with psoriatic arthropathy.

**Why Each Wrong Option is Incorrect**
* **Option A:** Methotrexate is a DMARD commonly used in the treatment of rheumatoid arthritis, but it may not be the most effective first-line treatment for psoriatic arthropathy.
* **Option B:** Corticosteroids can provide temporary relief from joint inflammation but are not recommended as a long-term treatment for psoriatic arthropathy due to their potential side effects.
* **Option C:** Hydroxychloroquine is a DMARD primarily used in the treatment of lupus and rheumatoid arthritis, and it may not be effective in managing the joint symptoms of psoriatic arthropathy.

**Clinical Pearl / High-Yield Fact**
When treating patients with psoriatic arthropathy, it is essential to consider the individual's skin and joint symptoms and adjust the treatment plan accordingly. Biologic agents such as etanercept and adalimumab have been shown to be effective in reducing joint inflammation and improving skin symptoms in these patients.

**Correct Answer:** A. Methotrexate is not the best choice here as the biologics are more commonly used, however the answer is not listed.